Related Experiment Video
Updated: Apr 25, 2026
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
Published on: May 17, 2015
The challenge of allograft vasculopathy in cardiac transplantation
1aDepartment of Cardiology, Oslo University Hospital Rikshospitalet bKG. Jebsen Cardiac Research Center and Center for Heart Failure Research, Faculty of Medicine, University of Oslo, Oslo, Norway.
Insights
Cardiac allograft vasculopathy (CAV) is a serious complication after heart transplants. Understanding its causes, diagnosis, and treatments is crucial for improving long-term survival in transplant recipients.
Area of Science:
- Cardiology
- Immunology
- Transplantation Medicine
Background:
- Cardiac allograft vasculopathy (CAV) is accelerated atherosclerosis unique to heart transplant recipients.
- CAV significantly impacts long-term survival post-transplantation.
- Increasing heart transplant rates necessitate a deeper understanding of CAV.
Purpose of the Study:
- To review recent advances in understanding CAV pathogenesis.
- To discuss accurate diagnostic methods for CAV, including emerging modalities.
- To explore current and future therapeutic strategies for CAV.
Main Methods:
- Review of complex immunological and non-immunological processes contributing to CAV.
- Evaluation of current and emerging diagnostic imaging techniques.
- Analysis of existing and novel treatment approaches for CAV.
Main Results:
- CAV involves endothelial activation and chronic inflammation leading to intimal hyperplasia.
- Accurate diagnosis is essential and achievable with appropriate imaging.
- Current immunosuppressive therapy shows limited efficacy, but newer agents show promise.
Conclusions:
- CAV is a critical determinant of long-term survival after heart transplantation.
- Effective diagnosis and treatment of CAV remain significant clinical challenges.
- Emerging immunosuppressive therapies offer hope for improved CAV management.
Purpose Of Review:
Cardiac allograft vasculopathy (CAV) is a unique form of accelerated atherosclerosis occurring in heart transplant recipients and this complication has a major negative impact on long-term survival. An understanding of recent advances in the understanding of CAV pathogenesis, accurate diagnosis and effective treatment is important given the increasing number of heart transplant procedures being performed annually.
Recent Findings:
This review article will discuss the complex immunological and nonimmunological processes that are likely to contribute to endothelial activation and the chronic inflammatory response causing intimal hyperplasia that is characteristic of CAV. Accurate diagnosis of CAV is essential, and both current and emerging imaging modalities will be reviewed. Finally, current treatment of CAV, together with future therapeutic strategies, will be discussed.
Summary:
CAV is an important complication-limiting survival after heart transplant, and a clear understanding of the underlying pathophysiological processes is important. The diagnosis of CAV can be difficult, but it is possible with the appropriate imaging modalities. Effective treatment of CAV remains an important clinical challenge, and current immunosuppressive therapy has limited efficacy. However, newer immunosuppressive agents have demonstrated promising results in clinical trials, and this will hopefully allow more effective disease management in the near future.
